2019 Webinar: Cannabis and the Liver: Update for the Hepatologist

5 (1 vote)

Recorded On: 12/12/2019

  • Registration Closed

Use of cannabis is growing in the population with increased interest in potential medicinal use as well as recreational use depending on the jurisdiction. Given this, clinicians need to have an understanding about cannabis and its potential impacts on liver disease. This webinar will provide attendees information about cannabis, its major components (THC/CBD) as well as discuss potential policy implications regarding transplantation. As well, the literature regarding safety and potential benefits/harms will be reviewed in detail. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

Stephen Congly (Moderator)

Dr. Stephen Congly is a Clinical Assistant Professor at the University of Calgary in the Division of Gastroenterology and Hepatology with a practice consisting of both general and transplant hepatology. He completed his internal medicine and gastroenterology training at the University of Calgary and subsequently a fellowship in Hepatology at the University of Calgary and in Transplant Hepatology at Mayo Clinic, Rochester, MN.

He has a Master of Science in Health Economics, Policy and Management from the London School of Economics and is a member of the O'Brien Institute for Public Health at the University of Calgary. His research interests include health technology assessment, resource utilization, hepatocellular carcinoma and liver transplantation.

Kevork Peltekian

Dr. Peltekian is the head of Division of Digestive Care and Endoscopy at the Queen Elizabeth II Health Sciences Centre and Professor of Medicine and Surgery at Dalhousie University. Since 1995, he has been practicing as a specialist in liver disease and transplantation in Nova Scotia. Over the years, Dr. Peltekian has been frequently recognized for excellence in undergraduate and postgraduate education as well as research. He has over 80 peer-reviewed publications in high impact journals. Over the years, he has held major leadership roles with Chairman and Chief Executive Officer of the Canadian Liver Foundation 2005-2009 and President of the Canadian Association for Study of Liver 2012-2014.

For his volunteer work and contributions to the fight against liver disease, Dr. Peltekian was awarded the Queen Elizabeth II Diamond Jubilee Medal. In 2017, Dr. Peltekian received the CASL Distinguished Service Award for his significant contributions to the practice of Hepatology in Canada. He has been a member of AASLD since 1993.

Key:

Complete
Failed
Available
Locked
Cannabis and the Liver: Update for the Hepatologist
Open to view video.
Open to view video. Presenters: Stephen E. Congly, MD, MSc, FRCPC, FACP and Kevork Peltekian, MD, FRCPC Moderator: Stephen E. Congly, MD, MSc, FRCPC, FACP
Final Evaluation
Final Evaluation
4 Questions
4 Questions Please complete the following evaluation form to share your feedback on this activity.